1 Min Read
Aug 22 (Reuters) - Versartis Inc
* Announces completion of enrollment in phase 3 Velocity trial of Somavaratan in Pediatric GHD; line results are anticipated in q3 2017. Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.